March 9th 2025
By Skylar Jeremias
Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
March 7th 2025
Celltrion's Omlyclo (omalizumab-igec) is the first omalizumab biosimilar to be approved for US patients, and it was approved with interchangeability, making it easier for patients to switch to the Xolair competitor.
By Cameron Santoro
Here are the top 5 biosimilar articles for the week of March 3, 2025.
March 6th 2025
Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
March 5th 2025
By Kennedy Ferruggia
Adalimumab biosimilars differ from adalimumab in approved indications, concentration and dosage, and formulation.
March 4th 2025
The approvals for Celltrion's denosumab-bmwo (Stoboclo and Osenvelt) mark the third FDA green light for a biosimilar to treat osteoporosis and bone metastases.
March 3rd 2025
By Deana Ferreri, PhD
A prospective cohort study found that switching back from the biosimilar SB2 to the reference infliximab did not affect clinical disease activity or safety in inflammatory bowel disease (IBD).
March 1st 2025
By Rose McNulty
February brought policy updates and several biosimilar approvals, including the first FDA approval for an insulin aspart biosimilar.
February 28th 2025
Here are the top 5 biosimilar articles for the week of February 24, 2025.
February 27th 2025
Patients with non-small cell lung cancer (NSCLC) taking bevacizumab biosimilars demonstrated equivalent therapeutic efficacy and similar safety profiles to those taking the originator product, Avastin.
